
Sophisticated analytical technologies are complementing traditional approaches in the identification of residual process-related impurities of biotherapeutics.
Stuart Pengelley is the senior scientist, Biopharma Application Development for Bruker Daltonics.
Published: July 15th 2021 | Updated: